Thursday, 06 August 2020


Pfizer launches targeted therapy for lung cancer in Singapore

04 August 2015 | Regulatory | By BioSpectrum Bureau

Pfizer launches targeted therapy for lung cancer in Singapore

Xalkori received approval from the US Food and Drug Administration (FDA) in 2011

Xalkori received approval from the US Food and Drug Administration (FDA) in 2011

Singapore: Pfizer has launched Xalkori, a targeted therapy for ALK-positive non-small cell lung cancer (NSCLC), in Singapore.

Xalkori is used to treat patients with late-stage (locally advanced or metastatic) non-small cell cancer (NSCLC) with an abnormal anaplastic lymphoma kinase (ALK) gene.

A targeted oral medication, Xalkori blocks certain proteins called kinases, including the protein produced by the abnormal ALK gene. Xalkori is taken twice a day as a single-agent treatment. It was shown that cancer patients responded more positively to this oral medication,with greater improvement in quality of life and fewer drug discontinuations due to treatment-related adverse events compared to standard chemotherapy.

Xalkori received approval from the US Food and Drug Administration (FDA) in 2011 and was the first ALK+ Non Small Cell Lung Cancer targeted therapy drug to be approved by the US FDA.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls